The ABCs of immunotherapy for adult patients with B-cell acute lymphoblastic leukemia Journal Article
| Authors: | Horvat, T. Z.; Seddon, A. N.; Ogunniyi, A.; King, A. C.; Buie, L. W.; Daley, R. J. |
| Article Title: | The ABCs of immunotherapy for adult patients with B-cell acute lymphoblastic leukemia |
| Abstract: | Objective: To review the pharmacology, efficacy, and safety of Food and Drug Administration approved and promising immunotherapy agents used in the treatment of acute lymphoblastic leukemia (ALL). Data Sources: A literature search was performed of PubMed and MEDLINE databases (1950 to July 2017) and of abstracts from the American Society of Hematology and the American Society of Clinical Oncology. Searches were performed utilizing the following key terms: rituximab, blinatumomab, inotuzumab, ofatumumab, obinutuzumab, Blincyto, Rituxan, Gazyva, Arzerra, CAR T-cell, and chimeric antigen receptor (CAR). Study Selection/Data Extraction: Studies of pharmacology, clinical efficacy, and safety of rituximab, ofatumumab, obinutuzumab, inotuzumab, blinatumomab, and CAR T-cells in the treatment of adult patients with ALL were identified. Data Synthesis: Conventional chemotherapy has been the mainstay in the treatment of ALL, producing cure rates of approximately 90% in pediatrics, but it remains suboptimal in adult patients. As such, more effective consolidative modalities and novel therapies for relapsed/refractory disease are needed for adult patients with ALL. In recent years, anti-CD20 antibodies, blinatumomab, inotuzumab, and CD19-targeted CAR T-cells have drastically changed the treatment landscape of B-cell ALL. Conclusion: Outcomes of patients with relapsed disease are improving thanks to new therapies such as blinatumomab, inotuzumab, and CAR T-cells. Although the efficacy of these therapies is impressive, they are not without toxicity, both physical and financial. The optimal sequencing of these therapies still remains a question. © 2017, © The Author(s) 2017. |
| Keywords: | cancer chemotherapy; review; drug efficacy; drug safety; cancer patient; rituximab; t lymphocyte; cancer immunotherapy; food and drug administration; acute lymphoblastic leukemia; immunotherapy; chimeric antigen receptor; seizure; immunomodulating agent; cd19 antigen; adverse event; inotuzumab ozogamicin; ofatumumab; blinatumomab; human; priority journal; obinutuzumab; drug antibody; car t-cells; inotuzumab |
| Journal Title: | Annals of Pharmacotherapy |
| Volume: | 52 |
| Issue: | 3 |
| ISSN: | 1060-0280 |
| Publisher: | Sage Publications |
| Date Published: | 2018-03-01 |
| Start Page: | 268 |
| End Page: | 276 |
| Language: | English |
| DOI: | 10.1177/1060028017736539 |
| PROVIDER: | scopus |
| PUBMED: | 29025266 |
| DOI/URL: | |
| Notes: | Review -- Export Date: 1 March 2018 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work